Nevan Charles Elam, Rezolute CEO (Softhale)

An­oth­er pub­lic biotech hops on the tri­al-win-to-stock-sale train, net­ting a nine-fig­ure raise

Af­ter un­veil­ing Phase II da­ta that, ac­cord­ing to Re­zo­lute, “ex­ceed­ed ex­pec­ta­tions” with a drug for con­gen­i­tal hy­per­in­sulin­ism, the Sil­i­con Val­ley-based biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.